- The Epstein-Barr virus (EBV), a member of the herpesvirus family, is one of the most common human viruses linked to infectious mononucleosis and a range of malignancies including nasopharyngeal carcinoma and certain lymphomas. The market for EBV drugs is shaped by growing recognition of its oncogenic role and ongoing efforts to develop disease-modifying therapies
- The demand for Epstein-Barr virus (EBV), is significantly driven by growing recognition of its oncogenic role and ongoing efforts to develop disease-modifying therapies
- North America dominates the EBV drug market due to a high prevalence of EBV-associated disorders, robust clinical research infrastructure, and access to innovative antiviral therapies
- Asia-Pacific is projected to grow at the fastest pace due to increasing incidence of EBV-related cancers, improving diagnostic capabilities, and expanding oncology treatment access, particularly in China and Southeast Asia
- Antiviral agents are expected to account for the largest market share of 43.23% in 2025, owing to their central role in suppressing viral replication and disease progression. The introduction of combination regimens and investigational agents further boosts this segment
